| 1 | 28817486 | Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China. | J Cardiovasc Pharmacol | 2017 Dec |
1 |
| 2 | 29154109 | Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. | J Pharm Biomed Anal | 2018 Feb 5 |
1 |
| 3 | 29209217 | Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans. | Front Pharmacol | 2017 |
10 |
| 4 | 29973877 | Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers. | Front Pharmacol | 2018 |
2 |
| 5 | 30326264 | Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. | Eur J Pharm Sci | 2019 Jan 15 |
4 |
| 6 | 30358688 | Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice. | J Cardiovasc Pharmacol | 2018 Nov |
1 |
| 7 | 30825385 | Enhanced responsiveness of platelets to vicagrel in IL-10-deficient mice through STAT3-dependent up-regulation of the hydrolase arylacetamide deacetylase in the intestine. | Br J Pharmacol | 2019 Jun |
11 |
| 8 | 31060007 | Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation. | Biomed Pharmacother | 2019 Jul |
3 |
| 9 | 31977858 | Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor. | Medicine (Baltimore) | 2020 Jan |
1 |
| 10 | 32267573 | Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y<sub>12</sub> inhibitor. | Br J Clin Pharmacol | 2020 Sep |
4 |
| 11 | 33244163 | Pharmacokinetics, mass balance, and metabolism of [<sup>14</sup>C]vicagrel, a novel irreversible P2Y<sub>12</sub> inhibitor in humans. | Acta Pharmacol Sin | 2021 Sep |
1 |
| 12 | 33424602 | Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach. | Front Pharmacol | 2020 |
12 |
| 13 | 33935793 | Corrigendum: Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach. | Front Pharmacol | 2021 |
2 |
| 14 | 34910929 | Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions. | Chem Biol Interact | 2022 Jan 25 |
16 |
| 15 | 35438151 | Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention. | Eur Heart J Cardiovasc Pharmacother | 2022 Apr 19 |
1 |